Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Esther N. Pijnappel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4998-9732; OpenAlex author ID A5035139276. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2021: 2 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. First author DOI 10.1016/j.ejca.2026.116683↗
  2. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  3. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
  4. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  5. The fear of cancer recurrence and progression in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-022-06887-w↗
  6. Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. Co-author DOI 10.3389/fonc.2022.839779↗
  7. Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13194869↗
  8. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. Co-author DOI 10.6004/jnccn.2021.7028↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna W. Wilmink · 8 shared papers, 2021–2026 · strength 1.35
  2. Judith de Vos‐Geelen · 6 shared papers, 2021–2026 · strength 1.11
  3. Hanneke W.M. van Laarhoven · 7 shared papers, 2021–2025 · strength 1.08
  4. Marc G. Besselink · 5 shared papers, 2021–2025 · strength 0.72
  5. Lydia G. van der Geest · 4 shared papers, 2021–2025 · strength 0.70
  6. Anne M. Gehrels · 2 shared papers, 2025–2026 · strength 0.48
  7. Marjolein Y.V. Homs · 3 shared papers, 2021–2025 · strength 0.46
  8. Martijn W.J. Stommel · 2 shared papers, 2025 · strength 0.45
  9. Ignace H. J. T. de Hingh · 2 shared papers, 2022 · strength 0.27
  10. Simona Casalino · 1 shared paper, 2026 · strength 0.27
  11. Davide Melisi · 1 shared paper, 2026 · strength 0.27
  12. Gerald W. Prager · 1 shared paper, 2026 · strength 0.27
  13. Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.27
  14. Geert‐Jan Creemers · 2 shared papers, 2021–2022 · strength 0.25
  15. Bas Groot Koerkamp · 2 shared papers, 2022 · strength 0.24
  16. Casper H.J. van Eijck · 2 shared papers, 2022 · strength 0.24
  17. Annette A. van Zweeden · 1 shared paper, 2025 · strength 0.24
  18. Jeanin Elise van Hooft · 1 shared paper, 2025 · strength 0.24
  19. Henk M.W. Verheul · 1 shared paper, 2025 · strength 0.24
  20. Lois A. Daamen · 1 shared paper, 2025 · strength 0.21
  21. Pauline A. J. Vissers · 1 shared paper, 2025 · strength 0.21
  22. Simone Augustinus · 1 shared paper, 2022 · strength 0.15
  23. Izaak Quintus Molenaar · 1 shared paper, 2022 · strength 0.15
  24. Hjalmar C. van Santvoort · 1 shared paper, 2022 · strength 0.13
  25. Dick J. Richel · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.